Clinical Trial Update: Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of BIBF 1120 (nintedanib) in patients with advanced gynecologic cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• BIBF 1120 (nintedanib) (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Genital Neoplasms, Female | Phase 1 | Status: COMPLETED